A Phase I Study of E7050 in Subjects With Solid Tumors
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the tolerability, safety, pharmacokinetics (PK),
pharmacodynamics (PD) and anti-tumor activity of E7050 when administered orally once daily to
patients with advanced solid tumor and gastric cancer.